Sumitomo Pharma Switzerland GmbH
Quick facts
Marketed products
- Cultured Thymus Tissue · Immunology
Cultured thymus tissue provides thymic factors and hormones that support immune system development and T-cell maturation. - Relugolix + Estradiol + Norethindrone Acetate · Gynecology / Endometriosis
Relugolix suppresses luteinizing hormone and follicle-stimulating hormone by antagonizing GnRH receptors, while estradiol and norethindrone acetate provide hormone replacement to manage menopausal symptoms in women with endometriosis.
Phase 3 pipeline
- Relugolix Combination Tablet · Oncology
Relugolix combination tablet works by inhibiting gonadotropin-releasing hormone (GnRH) receptors, leading to a decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production, which in turn reduces testosterone levels. - Relugolix Combination Therapy · Oncology
Relugolix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to rapid reduction of testosterone and estrogen levels.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Sumitomo Pharma Switzerland GmbH portfolio CI brief
- Sumitomo Pharma Switzerland GmbH pipeline updates RSS
Frequently asked questions about Sumitomo Pharma Switzerland GmbH
What are Sumitomo Pharma Switzerland GmbH's marketed drugs?
Top marketed products include Cultured Thymus Tissue, Relugolix + Estradiol + Norethindrone Acetate.
What is Sumitomo Pharma Switzerland GmbH's pipeline?
Sumitomo Pharma Switzerland GmbH has 2 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include Relugolix Combination Tablet, Relugolix Combination Therapy.
Related
- Cultured Thymus Tissue · Immunology
- Relugolix + Estradiol + Norethindrone Acetate · Gynecology / Endometriosis
- Sector hub: All tracked pharma companies